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Abstract
 
We report here a relationship between intramolecular epitope spreading and the clinical onset
of the endemic form of pemphigus foliaceus in a Brazilian community with a high prevalence
and incidence of the disease. Also known as Fogo Selvagem (FS), this disease is characterized by
severe skin blistering and pathogenic anti–desmoglein-1 (Dsg1) autoantibodies. These autoan-
tibodies bind the Dsg1 ectodomain and trigger keratinocyte cell detachment, the hallmark of
FS. We show that (a) sera from FS patients in the preclinical stage recognized epitopes on the
COOH-terminal EC5 domain of Dsg1, (b) disease onset was associated with the emergence of
antibodies specific for epitopes on the NH
 
2
 
-terminal EC1 and EC2 domains, (c) all sera from
FS patients with active disease recognized the EC1 and/or EC2 domains, and (d) sera from FS
patients in remission showed reactivity restricted to EC5. These results suggest that anti-Dsg1
autoantibodies in FS are initially raised against the COOH-terminal EC5 domain of Dsg1 in
individuals without skin disease; in genetically predisposed subjects the autoimmune response
may then undergo intramolecular epitope spreading toward epitopes on the NH
 
2
 
-terminal
EC1 and EC2 domains of Dsg1 leading to disease onset. Moreover, intramolecular epitope
spreading may also modulate remissions and relapses of FS.
Key words: autoimmunity • autoantibodies • desmogleins • epitope spreading • pemphigus
 
Introduction
 
Pemphigus foliaceus (PF)
 
*
 
 is a cutaneous autoimmune blis-
tering disease mediated by autoantibodies to desmoglein-1
(Dsg1), an epidermal cell adhesion molecule. These au-
toantibodies are predominantly of the IgG4 subclass (1) and
are pathogenic as demonstrated by passive transfer into
neonatal mice (1). The pathogenic mechanism of skin
blistering caused by these autoantibodies is not fully un-
derstood. Several mechanisms have been proposed, includ-
ing antibody-induced transmembrane signal transduction
activation (2) and direct blocking of the adhesive site of
Dsg1 by bound antibody (3). Dsg1 is a 160-kD desmo-
somal core glycoprotein that belongs to the cadherin family
of calcium-dependent cell adhesion molecules. Like other
members of this family, its ectodomain is composed of five
domains (EC1 to EC5). The first four domains (EC1-EC4)
are cadherin homologous repeats that contain six putative
calcium-binding sites; whereas, EC5 is a short membrane-
proximal region with no significant homology to the other
cadherin repeats. The epitopes recognized by PF sera are
conformationally sensitive (4) and calcium-dependent (5,
6). Pathogenic anti-Dsg1 antibodies target the extracellular
domain of Dsg1 (7, 8) and the majority of PF sera tested
recognize the NH
 
2
 
-terminal region of the molecule (9, 10).
Endemic PF, also known as fogo selvagem (FS), occurs
in rural populations of certain states of Brazil. The clinical,
histological, and immunological features of FS are not dis-
tinguishable from those of nonendemic PF (11, 12); how-
ever, unlike nonendemic PF, FS exhibits geographic and
familial clustering and the disease additionally affects young
adults and children (13). Since 1994, we have been follow-
ing a Brazilian Amerindian population (Terena tribe) ex-
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Abbreviations used in this paper:
 
 Dsg1, desmoglein-1; Dsg3, desmoglein-3;
FS, fogo selvagem; His, histidine; IF, immunofluorescence; IP, immuno-
precipitation; PF, pemphigus foliaceus; PV, pemphigus vulgaris.T
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hibiting a high prevalence (3.4%) of FS (14). Representing a
unique model to study etiology and pathogenesis of FS, this
Terena tribe lives in the reservation of Limao Verde in the
state of Mato Grosso do Sul, Brazil. More than 50% of
Limao Verde FS patients have at least one genetically related
family member affected with the disease. Using a highly sen-
sitive ELISA technique, we detected low levels of anti-Dsg1
autoantibodies in 55% of normal subjects (
 
n
 
 
 
  
 
93) living in
Limao Verde and in FS patients several years before the clin-
ical onset of disease (15). Consistent with the hypothesis that
FS is triggered by an unidentified environmental factor(s),
the percentage of Dsg1 antibody-positive individuals de-
creases in populations with increasing distance from the en-
demic focus of Limao Verde. Subsequent IgG subclass analy-
ses revealed that the transition from preclinical to clinical
disease is associated with a marked increase of anti-Dsg1 au-
toantibodies, predominantly of the IgG4 subclass (16).
To understand the etiology and immunopathology of
FS, we sought to compare the epitope profiles of anti-Dsg1
autoantibodies present in normal subjects living in Limao
Verde and in patients at different clinical stages of FS in-
cluding preclinical and clinical disease, remission, and re-
lapse. Our data suggest that FS autoimmunity evolves from
a nonpathogenic response against the EC5 domain of Dsg1
to a pathogenic response against the EC1 and EC2 domains
of the molecule. In addition, disease remission and relapse
are strongly correlated with anti-Dsg1 epitope specificities.
 
Materials and Methods
 
Patients and Sera.
 
We studied a total of 40 sera from 28 FS
patients living in the Limao Verde Amerindian reservation (Mato
Grosso do Sul, Brazil). The clinical, histological and serological
features of most of these patients have been published previously
(14). These patients showed skin lesions typical of FS and no
mucosal lesions.
The 28 FS patients included 20 patients with active disease ex-
hibiting typical skin lesions and 8 patients, with no skin lesions,
considered to be in clinical remission. The 20 FS patients with
active disease included six patients, early in the course of the dis-
ease, from whom serum samples were also available 1 to 7 yr be-
fore disease onset and another 14 patients. FS patients with active
disease were treated initially with prednisone using doses that
ranged from 30 to 60 mg per day. Once a patient entered clinical
remission, the steroids were tapered over several months. Several
of these patients relapsed during the course of their therapy. All
serum samples were collected before the onset of therapy. The
indirect immunofluorescence (IF) titers of anti-epidermal anti-
bodies in patients with active disease ranged from negative to
1:640. Two patients in this group showed negative indirect IF ti-
ters, but showed anti-Dsg1 antibodies by a Dsg1-ELISA assay.
Of the eight patients in clinical remission, three patients re-
ceived no therapy for over 2 yr and the remaining five patients
were on maintenance therapy with prednisone (2.5 to 10 mg per
day). Seven of these eight patient sera had negative indirect IF
tests; in one patient (FS17) the serum showed titers below 1:40.
Sera from 12 normal donors from the Limao Verde reservation
were also included in this study. Among the 12 donors, 5 were
first-degree relatives to the patients and 7 were unrelated. All 12
donors had no evidence of skin disease, but contained anti-Dsg1
 
autoantibodies by ELISA (15). The ELISA index values of the 12
sera ranged from 1.1 to 24.1 (cut-off value 0.92) with a mean
value of 7.7. The ELISA index and the cut-off value were as de-
scribed previously (15). 11 normal donor sera from the US were
also tested as controls.
The collected sera were stored at 
 
 
 
20
 
 
 
C and then transported
to our laboratories at the University of North Carolina, where
the immunological assays were performed. The study had the ap-
proval of FUNAI, a body representing the interests of the Indians
of Limao Verde, and the Institutional Review Boards of the Uni-
versity of North Carolina, Chapel Hill and the Universities of
Sao Paulo and Mato Grosso do Sul, Brazil.
 
Construction and Expression of Recombinant Antigens.
 
A dis-
tinct desmosomal core glycoprotein is desmoglein-3 (Dsg3), an
autoantigen of the related autoimmune skin blistering disease
known as pemphigus vulgaris (PV) (17). Dsg1 and Dsg3 have
similar molecular structures (Fig. 1 A), but exhibit distinct anti-
genic sites recognized by PF-IgG and PV-IgG (10). We have
previously constructed and expressed in baculovirus the entire
extracellular portion of the human Dsg1 and Dsg3 polypeptide
containing a COOH-terminal histidine (His) tag (18, 19).
In the current study, we engineered various combinations of
the extracellular domains (EC1 to EC5) of Dsg1 on the Dsg3
backbone (Fig. 1 B). Such domain swapping between homolo-
gous, but immune noncrossreactive proteins, has been used suc-
cessfully for mapping many conformational epitopes (20, 21), in-
cluding a recent study of Dsg1 and Dsg3 epitope mappings (10).
Eight chimeric molecules of Dsg1 and Dsg3 were constructed
from sixteen cDNA fragments encoding various domains of Dsg1
or Dsg3. These fragments were PCR amplified from human Dsg1
(GenBank accession no. X56654) and Dsg3 (GenBank accession
no. M76482) cDNAs in vector PVL1393 (18, 19). The sequences
of the PCR primers used are listed in Table I. BamHI and KpnI
endonuclease sites were included in the forward and reverse prim-
ers, respectively, for amplifying the upstream cDNA fragments.
Similarly, KpnI and NotI sites were introduced in the forward
and reverse primers, respectively, for amplifying the downstream
fragments. After digestion with appropriate restriction enzymes,
each set of upstream and downstream cDNA fragments were li-
gated at the KpnI site and subcloned into the BamHI and NotI
sites of the baculovirus expression vector pFastBac1 plasmid (Life
Technologies). As a result of addition of the KpnI site, two extra
residues of Glu and Ser were introduced at the junctions of Dsg1
and Dsg3 in these chimeric molecules. The coding region of the
constructs begins with the endogenous initial Met followed by a
signal sequence and a propeptide of Dsg1 or Dsg3, and a hybrid
extracellular domain of Dsg1 and Dsg3. All constructs were fused
with an in-frame COOH-terminal His tag, which enables us to
detect or affinity purify the chimeric proteins.
All chimeric cDNAs were sequenced to verify the expected
hybrid sequences. The chimeric constructs were expressed as se-
creted glycoproteins in a baculovirus expression system (Bac-
To-Bac; Life Technologies) according to the procedure pro-
vided by the manufacturer. High-five insect cells cultured in
Express-Five serum-free medium (Life Technology) were used
to produce the recombinant proteins. The yield of the recombi-
nant proteins ranged from 2 to 10 
 
 
 
g/ml supernatant. The
amounts of recombinant protein in these supernatants was esti-
mated by comparing the intensities of the specific protein bands
(shown by Western blots) produced by known amounts of puri-
fied recombinant Dsg1 and Dsg3. The concentration of purified
recombinant Dsg1 and Dsg3 was determined by the Bradford
assay (Bio-Rad Laboratories).T
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Immunoprecipitation Coupled with Immunoblotting.
 
The culture
supernatants of recombinant proteins (
 
 
 
0.5 
 
 
 
g recombinant pro-
tein) were incubated with each test serum (2 
 
 
 
l) in the presence
of 5 mM Ca
 
2
 
 
 
 overnight at 4
 
 
 
C. IgG-antigen immune complexes
were precipitated by incubation with 20 
 
 
 
l of a 50% suspension
of recombinant protein-G Sepharose 4B (Zymed Laboratories)
for 1.5 h at 4
 
 
 
C. After 3 washes with Tris-buffered saline (pH
7.2) containing 5 mM Ca
 
2
 
 
 
 and 0.1% Triton X-100, the pellet
was extracted with 2
 
 
 
 SDS sample buffer and boiled for 5 min.
The eluted supernatant was then fractionated by 10% SDS-PAGE
and analyzed by immunoblotting with an HRP-labeled anti-His
monoclonal antibody (1:3000 dilution of Penta-His HRP Con-
jugate; QIAGEN). Antigen bands were detected by enhanced
chemiluminesence (Amersham Biosciences).
To determine the spectrum of anti-Dsg1 autoantibody speci-
ficities, we analyzed the reactivity of each serum against a panel of
10 recombinant proteins (see Fig. 1 B). The entire extracellular
domain of Dsg1 was included as a positive control. We also in-
cluded the extracellular domain of Dsg3 to determine the back-
ground reactivity of each serum to the Dsg3 backbone.
 
Affinity-Purification and Pathogenicity of the Domain-specific Anti-
Dsg1 Autoantibodies.
 
Total IgG fractions from a patient with FS
exhibiting anti-Dsg1 antibodies specific for the EC1 and EC2 do-
mains only were purified by protein G affinity chromatography.
The anti-EC1–2 autoantibodies from the FS patient were affinity
purified using the recombinant chimeric protein Dsg1-EC1–2
bound to the Ni-NTA resin (QIAGEN) as described by Ding et
al. (19). Additionally, the IgG fraction was prepared from the se-
 
Table I.
 
PCR Primers Used in Construction of Recombinant Chimeric Proteins
 
Upstream fragments Downstream fragments
Primers Primers
PCR 
products Forward Reverse
PCR 
products Forward Reverse
Dsg1 fragments on
the Dsg3 backbone
Dsg1.EC1 1 2 Dsg3.EC2-5 6 10 EC1/Dsg3.EC2-5
Dsg1.EC1-2 1 3 Dsg3.EC3-5 7 10 EC1-2/Dsg3.EC3-5
Dsg1.EC1-3 1 4 Dsg3.EC4-5 8 10 EC1-3/Dsg3.EC4-5
Dsg1.EC1-4 1 5 Dsg3.EC5 9 10 EC1-4/Dsg5
Dsg3.EC1 11 12 Dsg1.EC2-5 16 10 EC2-5/Dsg3.EC1
Dsg3.EC1-2 11 13 Dsg1.EC3-5 17 10 EC3-5/Dsg1.EC3-5
Dsg3.EC1-3 11 14 Dsg1.EC4-5 18 10 EC4-5/Dsg3.EC1-3
Dsg3.EC1-4 11 15 Dsg1.EC5 19 10 EC5/Dsg3.EC1-4
Primer 1
 
5
 
 
 
-ATTCGGATCCCGCCATGGACTGGAGTTTCTTCAGAG
 
Primer 2
 
5
 
 
 
-GCCGGTACCAAACACTGGAGGGTTGTCATT
 
Primer 3
 
5
 
 
 
-GCCGGTACCCATGTAAGGGATATTATCATTGA
 
Primer 4
 
5
 
 
 
-GCCGGTACCAAACACTGGGCCTTCAATTAC
 
Primer 5
 
5
 
 
 
-GCCGGTACCAGTAATTTTAGTGTTCGGCTCT
 
Primer 6
 
5
 
 
 
-GCCGGTACCTCACAACAAATTTTCATGGGTG
 
Primer 7
 
5
 
 
 
-GCCGGTACCAGAGACTCTCAGTATTCAGCA
 
Primer 8
 
5
 
 
 
-GCCGGTACCCCTGCTTCCAAGACATTTACT
 
Primer 9
 
5
 
 
 
-GCCGGTACCACAGCTGTCCTCGAAAAAGAT
 
Primer 10
 
5
 
 
 
-GCCGCGGCCGCCTAGCGCGCGTGATGGTG
 
Primer 11
 
5
 
 
 
-CGGGGATCCCGCCATGGGGCTCTTCCCCAGAA
 
Primer 12
 
5
 
 
 
-GCCGGTACCAAATACTGGAGGATTATCATTAAT
 
Primer 13
 
5
 
 
 
-GCCGGTACCAAACATTGGGAAGTTATCGTTG
 
Primer 14
 
5
 
 
 
-GCCGGTACCGAATGCAATTCCTTCTCTTACA
 
Primer 15
 
5
 
 
 
-GCCGGTACCTGGACAATTGTCATTGAAATCG
 
Primer 16
 
5
 
 
 
-GCCGGTACCTCAATGGCTACATTTGCAGGA
 
Primer 17
 
5
 
 
 
-GCCGGTACCGAACAGTCTTCATATACCATAG
 
Primer 18
 
5
 
 
 
-GCCGGTACCCGTCCAGGTTCAAAGACATAT
 
Primer 19
 
5
 
 
 
-GCCGGTACCACCAATACTGGCAGACAAGAAT
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rum of a normal individual from Limao Verde by Protein G af-
finity chromatography. This serum possessed high levels of anti-
Dsg1 antibodies specific for the EC5 domain of the molecule.
The specificity of the purified antibody fractions was confirmed
by immunoprecipitation assays.
The pathogenicity of the anti-Dsg1 antibodies present in puri-
fied total IgG and purified anti-EC1-EC2 antibody fraction was
tested by passive transfer experiments as we have described previ-
ously (1, 19). Briefly, BALB/c mice (24–36 h old with body
weights 1.4 to 1.6 g) were injected intradermally with 100 
 
 
 
l ali-
quots of purified antibodies in PBS buffer. The doses of IgG are
shown in Table II. The skin of neonatal mice was examined 18 h
after the IgG injection. Skin sections were obtained for routine
histopathological and direct immunofluorescence analysis.
 
Statistical Analysis.
 
Fisher’s exact test was used to compare
proportions in different groups of patients. The preonset versus
post-onset comparison in the same patients was done with Mc-
Nemar’s test (exact P values reported).
 
Results
 
Construction and Baculovirus Expression of Recombinant
Dsg1, Dsg3, and Chimeric Dsg1/Dsg3 Autoantigens.
 
We
constructed eight chimeric molecules consisting of various
ectodomain segments of Dsg1 (EC1, EC1–2, EC1–3,
EC1–4, EC2–5, EC3–5, EC4–5, and EC5) grafted on the
Dsg3 backbone and fused with a COOH-terminal His-tag
(depicted in Fig. 1 B). 10 recombinant proteins were pro-
duced in the baculovirus system, including the full-length
extracellular domain of Dsg1, the full-length extracellular
domain of Dsg3, and eight chimeras containing various
combinations of the extracellular domains of Dsg1 and
Dsg3. Fig. 1 C shows anti-His tag immunoblot analysis of
the 10 recombinant proteins secreted in the insect culture
medium. It should be noted that the recombinant proteins
were often expressed as a doublet, a phenomenon also no-
ticed previously for the recombinant Dsg1 (8) and Dsg3
(22) produced by baculovirus. It has been suggested that
the upper band represents the protein bearing the un-
cleaved propeptide due to the inefficiencies of proteolytic
processing in the baculovirus expression system.
 
Sera from Normal Subjects Living in an Area Endemic for
FS Recognize the EC5 Domain of Dsg1.
 
In the present
epitope mapping study we selected 12 sera from normal
subjects living in Limao Verde and showing relatively high
Dsg1-ELISA index values. These sera were tested against a
panel of 10 recombinant proteins (see Fig. 1, B and C) by
immunoprecipitation (IP) assay. Representative IP results
are shown in Fig. 2. All sera tested reacted with the full-
length extracellular domain of Dsg1 (Fig. 2, lane 1) and
chimeras that harbored the EC5 domain of Dsg1, includ-
ing EC2–5 (Fig. 2, lane 7), EC3–5 (Fig. 2, lane 8), EC4–5
(Fig. 2, lane 9), and EC5 (Fig. 2, lane 10). It should be
noted that the reaction of the sera with the EC2–5 (Fig. 2,
lane 7) and EC4–5 chimeras (Fig. 2, lane 9) was often
weaker (Fig. 2, also seen in Fig. 3, and Fig. 6, A and B be-
low) than the reaction of the other two EC5-containing
chimeras (Fig. 2, lanes 8 and 10). The lower reactivity of
these Dsg1 chimeras may be due to a slightly altered fold-
ing of these hybrid molecules, thus making the EC5 do-
main less accessible.
By contrast, the 11 normal sera from US donors showed
only negative or background reactivities when tested
against either the full-length extracellular domains of Dsg1
or the chimeric protein containing the EC5 domain of
Dsg1 (data not depicted).
Figure 1. Schematic diagram and baculovirus production of Dsg1,
Dsg3, and chimeric antigens. (A) Molecular structure of Dsg1 and Dsg3.
Dsg1 and Dsg3 are structurally similar desmosomal transmembrane glyco-
proteins. The extracellular domain of the two molecules contains four
cadherin-like domains (EC1 to EC4) and a membrane-proximal domain
(EC5). Sequence identities between the cadherin repeats of Dsg1 and
Dsg3 are indicated. NS indicates that sequence homology between the
two molecules in the EC5 domain is not significant (reference 39). The
black stripes represent six putative Ca2  binding motifs found in the cad-
herin repeats. (B) Diagram of the recombinant Dsg1, Dsg3, and eight chi-
meric proteins. We constructed the full-length extracellular domains of
Dsg1, Dsg3, and eight hybrid molecules that contained various combina-
tions of Dsg1 extracellular domains (open box) with the corresponding
Dsg3 (straight line) backbone. All recombinant proteins contain the en-
dogenous signal sequence, a propeptide, and the extracellular domain of
Dsg1/Dsg3 fused with a COOH-terminal His tag. (C) Production of the
10 recombinant proteins in the baculovirus expression system. The cul-
ture supernatants containing various secreted recombinant proteins (la-
beled on top of the figure) were collected and subjected to immunoblot-
ting using HRP-labeled monoclonal antibody against the common His
tag. Molecular weight standards are shown at left.T
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The Transition from the Preclinical to the Clinical Stage of FS
Is Associated with Apparent Epitope Spreading from EC5 to
EC1 and EC2 of Dsg1.
 
The observation that anti-Dsg1
autoantibodies from healthy individuals targeted the EC5
domain of Dsg1 suggests that anti-Dsg1 autoantibodies in
FS might be initially raised against the EC5 domain of
Dsg1. To test this hypothesis, we examined epitope speci-
ficities of anti-Dsg1 autoantibodies from six FS patients
from whom sequential blood samples were available before
and after the onset of disease. Fig. 3 shows the antibody re-
activity of the sera obtained before (Fig. 3, left panel) and
after (Fig. 3, right panel) disease onset. Low levels of anti-
Dsg1 autoantibodies were present 1 to 7 yr before the clini-
cal onset of FS (Fig. 3, left panel, lane 1). These preclinical
sera bound the full-length extracellular domain of Dsg1
(Fig. 3, left panel, lane 1) and EC5 bearing chimeras (Fig. 3,
lanes 7–10). Four sera (FS29, FS30, FS32, and FS38) from
the preclinical stage bound the extracellular domain of Dsg3
(Fig. 3, lane 2), although the reaction was much weaker
than the reactivity produced with Dsg1 (Fig. 3, lane 1).
A considerable increase of anti-Dsg1 autoantibodies was
observed in sera obtained after the onset of clinical disease
(right panel, lane 1). Interestingly, all serum samples at this
stage reacted with chimeras containing the EC1 (right
panel, lanes 3–6) and/or EC2 (lanes 4–7) domains of Dsg1.
Three of the 4 sera, which reacted weakly with Dsg3 dur-
ing the preclinical stage, continued recognizing Dsg3 dur-
ing the active stage of FS (FS29, FS30, and FS32, right
panel, lane 2).
Comparing the proportion of positive tests for anti-EC1
antibodies in the preclinical and clinical stage sera in six pa-
tients with pre and post-onset data, we found a statistically
significant difference (P 
 
 
 
 0.016).
 
Anti-EC5 Autoantibodies from Normal or Preclinical Individ-
uals Do Not React with the Human Epidermis.
 
We further
tested the binding of the anti-EC5 sera to human epidermis
by indirect IF. As shown in Fig. 4, FS sera possessing anti-
EC1 and anti-EC2 reactivity stained human skin sections
(Fig. 4, left panel). In contrast, anti-EC5 sera from all the
12 normal subjects tested and 6 preclinical FS patients sera
showed negative staining. A representative result is shown
on the right panel. This result suggests that anti-Dsg1 au-
toantibodies in normal or preclinical individuals do not
bind to human epidermis, as assayed by indirect IF, al-
though they are detectable by IP or ELISA.
 
All Sera from Patients with Active Disease Recognize the EC1
and/or EC2 Domains of Dsg1.
 
We then examined sera
from 14 patients with active disease. Representative results
are shown in Fig. 5. These sera produced four epitope pro-
files or reaction patterns when tested with Dsg1 chimeras
by IP. Pattern 1 was produced by nine sera (64%) and
showed strong reactivity with chimeras containing the EC1
Figure 2. Analysis of anti-Dsg1 antibodies from normal subjects living
in an area endemic for FS. Each serum sample was immunoprecipitated
with 10 recombinant proteins (labeled on top of each panel), respectively,
and subjected to immunoblotting using a monoclonal antibody against
the His tag. IP results from three normal individuals living in the Limao
Verde of Brazil are shown.
Figure 3. Antibody specificities from FS
patients before and after the clinical onset of
disease. Sera from six patients before (left
panel) or after (right panel) clinical disease
onset were analyzed by IP. Left panel: the
time intervals between the preclinical sera
and disease onset are indicated at left. y:
year(s); m: months. Right panel: sera from
patients FS29, FS32, and FS33 were collected
after 3, 2, or 9 mo, respectively after the first
symptoms of FS observed; sera from patients
FS30, FS38, and FS39 were collected within
the same month of disease onset.T
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and EC2 domains (Fig. 5, lanes 3–7), but very little reactiv-
ity with chimeras that did not contain these domains (Fig.
5, lanes 8–10). A patient (FS12) during a severe clinical re-
lapse of the disease showed the same reaction pattern (see
Fig. 6 B below). Pattern 2 was produced by one serum
only (7.1%). This serum recognized chimeras bearing only
the EC1 domain in common (Fig. 5, lanes 3–6); it was
barely reactive with chimeras lacking EC1 (Fig. 5, lanes
7–10). This pattern was also produced by the serum of pa-
tient FS39 at disease onset (see Fig. 3). Pattern 3 was seen
with one serum (7.1%) that reacted with EC2 domain only
(Fig. 5, lanes 4–7), but showed little or no reactivity with
EC1 (Fig. 5, lane 3). The serum of patient FS17 also
showed similar pattern during the active phase of the dis-
ease (see Fig. 6 B). Pattern 4 was produced by three sera
(21.5%), which reacted with all Dsg1 chimeras tested (Fig.
5, lanes 3–10). This epitope profile was also observed when
testing the sera of four patients shortly after disease onset
(FS29, FS30, FS32, and FS38, Fig. 3) and the sera from two
patients during clinical relapses (FS12-Dec. 96 and FS20-
Mar. 95, in Fig. 6 B).
Since all sera showing reaction pattern 4 recognized the
EC1 (Fig. 5, lane 3) and the EC5 domains (Fig. 5, lane 10),
it is likely that the reactivity observed with other chimeras
(Fig. 5, lanes 4–9) are due to the presence of anti-EC1
(EC1 domain is common to chimeras of lanes 3–6) and
anti-EC5 antibodies (EC5 domain is common to chimeras
of lanes 4–10) in these sera. However, we cannot rule out
the possibility that these sera may also recognize the EC2,
EC3, or EC4 domains.
There was a significant difference between patients with
active disease (
 
n
 
 
 
  
 
20) and normal subjects (
 
n
 
 
 
  12) in the
percentage of sera recognizing the EC1 (P   0.0001), EC2
(P   0.001), and EC5 reactivity (P   0.001) domains.
Sera from Patients in Clinical Remission Reacted with the
EC5 Domain Only. Similar to the epitope profiles ob-
served in sera from normal subjects (see Fig. 2) or from pa-
tients in the preclinical stage (see Fig. 3, left panel), the sera
from patients in clinical remissions (n   8) all predomi-
nantly recognized the EC5 domain. Fig. 6 A shows the
epitope profile of the three FS patients in complete remis-
sion for more than 2 yr without therapy (FS2, FS3 and
FS25). Fig. 6 B shows the reaction patterns produced by
another three patients in clinical remission on low mainte-
nance steroid therapy (FS12, FS17, and FS20). The re-
maining 2 sera showed similar results. There was a signifi-
cant difference between patients with active disease (n  
20) and patients in remission (n   8) in the percentage of
sera recognizing the EC1 (P   0.001), EC2 (P   0.01),
and EC5 reactivity (P   0.003) domains.
Dynamic Changes of Epitope Specificities during Disease Re-
mission and Relapses in Individual Patients. To observe dy-
namic changing of epitope profiles, we determined the an-
tibody specificities of sequential sera from FS patients (n  
5) during different clinical stages of the disease (active, re-
mission, and relapse). Three representative patients (FS12,
FS17, and FS20) are shown in Fig. 6 B.
Serum from patient FS12 during clinical remission
(March 1994) predominantly reacted with EC5 containing
chimeras (Fig. 6 B, lanes 7–10). A mild clinical relapse in
December 1996 was heralded by the appearance of anti-
EC1 and anti-EC2 antibodies (Fig. 6 B, lanes 3–7) and
continuous anti-EC5 reactivity (Fig. 6 B, lanes 8–10). A se-
vere clinical relapse in March 1998 was associated with an
increase in the intensity of anti-EC1 and anti-EC2 reactivi-
ties and the disappearance of anti-EC5 antibodies.
Serum from patient FS17 during active disease (March
1994) reacted with EC2 containing chimeras (Fig. 6 B,
lanes 4–7) and, to a lesser extent, with EC5 containing chi-
meras (Fig. 6 B, lanes 8–10). As the disease entered clinical
remission (March 1996), anti-EC2 reactivity (Fig. 6 B, lanes
4–6) declined significantly. The weak reaction of FS17 (in
remission) with EC1 containing chimeras (Fig. 6 B, lanes
3–6) is likely due to reactivity with the Dsg3 backbone
since this serum also recognized Dsg3 (Fig. 6 B, lane 2).
Serum from patient FS20 in clinical remission (March
1994) predominantly reacted with EC5 containing chime-
ras (Fig. 6 B, lanes 7–10). In addition to reacting with Dsg1
(Fig. 6 B, lane 1), this serum also reacted weakly with Dsg3
(Fig. 6 B, lane 2). A mild clinical relapse in 1995 was asso-
ciated with an increase in reactivity with EC1/EC2 con-
taining chimeras (Fig. 6 B, lanes 3–6), and a decrease of re-
Figure 4. Indirect IF analysis of anti-EC1/EC2 and anti-EC5 sera on
the human epidermis. Left panel: a serum from a FS patient with anti-
Dsg1 antibodies specific for the EC1 and EC2 domains. Right panel: a
normal serum with anti-Dsg1 antibodies specific for the EC5 domain
of Dsg1.
Figure 5. Epitope profiles of anti-Dsg1 antibodies from patients with
active disease. IP results from four representative FS patients with active
disease are shown. The number of sera within this group (n   14) show-
ing similar reaction patterns is indicated at right.T
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activity with Dsg3, which declined to background (Fig. 6
B, lane 2).
Antibody Reactivity with Dsg3 in Different Groups of Sera
Tested. We found several sera from normal controls and FS
patients that recognized the full-length ectodomain of Dsg3.
The intensity of the Dsg3 IP reaction varied from weak, in
the majority of sera, to fairly strong in a small group of sera.
We detected anti-Dsg3 antibodies by IP in the following
groups of sera: (a) in 2 out of 12 sera from normal donors
from Limao Verde (same group possessing anti-Dsg1 anti-
bodies), (b) in the sera of 3 patients before and after the on-
set of FS (FS29, FS30, and FS32; shown in Fig. 3, left and
right panel), (c) in one FS patient (FS38) 3 yr and 10 mo
before the onset of the disease (shown in Fig. 3, the left
panel), (d) in 2 of 20 patients with active FS, and (e) in 3
out of 8 patients in clinical remission (shown in Fig. 6 B,
FS12, FS17, and FS20). The intensity of the IP reaction
with Dsg3 was much weaker than that observed with Dsg1
in all groups of sera tested.
In summary, of the 28 FS patients tested, 5 sera (FS29,
FS30 and FS32, shown in Fig. 3, right panel, and FS17 and
FS20, shown in Fig. 6 B) demonstrated good IP reactivity
with the full-length ectodomain of Dsg3.
It appears that the majority of sera showing anti-Dsg3 an-
tibodies recognized chimeras expressing the EC5 domain of
Dsg3 in common. This finding is shown in Fig. 3 (Fig. 6 B,
lanes 3–6, left panel with FS30 and FS32) and also in sera
from FS12, FS17 and FS20 in remission (see Fig. 6 B, lanes
3–6). Only one serum (from FS29 before disease onset) ap-
pears to bind the EC1 domain of Dsg3, as chimeras bearing
the EC2–5, EC3–5 EC4–5 and EC5 domain of Dsg3 (Fig.
3, lanes 3–6, left panel) did not produce any reaction.
Autoantibodies to the EC1/EC2 Domains of Dsg1 Are
Pathogenic, whereas the Anti-EC5 Autoantibodies Are Non-
pathogenic. We further tested the pathogenicity of the
anti-EC1/EC2 and anti-EC5 autoantibodies by passive
transfer experiments and the results are summarized in Ta-
ble II. Mice injected with total IgG (affinity-purified by
protein G) and EC1–2 domain-specific IgG (purified using
EC1-EC2 chimeras) obtained from a FS patient with active
disease developed skin lesions, which on histological exam-
ination revealed subcorneal acantholysis. In contrast, the
IgG fraction (affinity-purified by protein G) from a normal
unaffected donor from Limao Verde, possessing high titer
anti-Dsg1 antibodies specific for the EC5 domain, failed to
induce disease in neonatal mice. The lack of pathogenicity
of this IgG fraction was observed with a dose 10 times
higher than those injected with total pathogenic IgG from
a FS patient (see Table II).
Discussion
Since 1994, our clinical and serological surveillance of
the  1,200 individuals living in Limao Verde, Brazil has
revealed a 3.4% prevalence of FS (14). Moreover, a signifi-
cant pool of normal individuals (55%) living on the reserva-
tion possesses anti-Dsg1 antibodies (15). Follow up studies
of this settlement have shown an average of 2–3 new cases
of FS per year. In the present study, we have investigated
the evolution of the anti-Dsg1 autoimmune response in
these inhabitants. Our data showed that anti-Dsg1 antibod-
ies from those normal individuals and patients with FS be-
fore the onset of clinical disease all recognized the EC5 do-
main (residues 453–496) of the molecule. Significantly,
transition from the preclinical to clinical stage of FS was ac-
companied by emergence of autoantibodies specific for the
Figure 6. Antibody specificities from FS patients during the course of
disease. (A) IP results from three FS patients in long-term clinical re-
mission. (B) IP results from sequential sera samples obtained from
three representative patients (FS12, FS17, and FS20) during the course of
disease. Clinical outcomes and bleeding dates are labeled at right.
Table II. Pathogenicity of Anti-Dsg1 Autoantibodies Specific for 
the EC1-2 or EC5 Domains
IgG
Dose injected
(mg/g body
weight)
No. of
mice
tested
Skin
lesions
Acantholysis
(H&E)
Anti-EC1/EC2
Protein G purified 1.5 3   
EC1-2 purified 0.3 3   
Anti-EC5
Protein G purified 1.5 3   
15 3   T
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EC1 (residues 1–108) and EC2 (residues 109–221) do-
mains. Moreover, by passive transfer experiments we dem-
onstrated that anti-EC1/EC2 autoantibodies were patho-
genic using neonatal mice, whereas the IgG fraction
containing anti-EC5 autoantibodies was incapable of in-
ducing blisters in mice. These data suggest that the anti-
Dsg1 autoimmune response in FS is initially raised against
nonpathogenic epitopes located in the EC5 domain and
later against pathogenic epitopes mapped to the EC1 and
EC2 domains of the molecule. It is likely that anti-EC1/
EC2 autoantibodies are generated through the mechanism
of intramolecular epitope spreading (23, 24) from the initial
anti-EC5 autoantibodies rather than through the mecha-
nism of cross-reactivity, as there is no significant sequence
homology between the EC5 domain and the cadherin-like
domains (EC1 to EC4).
Epitope spreading is a phenomenon in which new
epitopes, within the same or a different molecule, are rec-
ognized over time by T cell or B cell from an original non-
cross-reactive antigenic site (23, 24). This phenomenon has
been well demonstrated in various experimentally induced
or spontaneous animal models of autoimmunity at both the
T cell and B cell levels (25). However, the evidence of
epitope spreading in human autoimmune diseases is limited
(25). Possible intramolecular epitope spreading has been
observed recently in six patients with systemic lupus
erythematosus in the anti-Sm B/B’ antibody system (26)
and patients with type 1 diabetes in the anti-GAD65 (27,
28) and anti–IA-2 (29) antibody systems. However, the
epitope spreading seen in these patients was not specifically
associated with onset of clinical disease.
The restricted anti-EC5 reactivity observed in normal
individuals living in an endemic focus of FS and in FS pa-
tients before the clinical onset of disease strongly suggests a
common immunological mechanism initiating Dsg1 au-
toimmune response. A unique feature of the anti-EC5 an-
tibodies, as observed in this study, is that they do not bind
Dsg1 in cryosections of human epidermis as demonstrated
by indirect IF. The negative staining of anti-EC5 sera on
human epidermis is unlikely due to the low titer of the an-
tibodies as many of these sera showed very high titers by
ELISA (15). We hypothesize that the EC5 domain, a very
short region close to the cell membrane, is sequestered in
vivo and consequently, unable to be bound by circulating
anti-EC5 antibodies. The cryptic nature of the EC5 do-
main is consistent with the concept that molecular mimicry
to cryptic self-peptides or exposure of cryptic self-peptides
elicits autoimmunity because normally there is a lack of
self-tolerance to cryptic epitopes.
Based on the current findings, we propose a two-phase
model to encompass the immunopathogenic mechanisms of
FS (Fig. 7). In the first phase, an environmental antigen(s),
bearing sequence homology with the EC5 domain of Dsg1,
triggers an initial nonpathogenic antibody response to the
EC5 domain of Dsg1. At this stage, individuals remain free
of skin disease. In the second phase, in certain genetically
susceptible individuals, intramolecular epitope spreading
occurs, which leads to the production of pathogenic anti-
Dsg1 antibodies against the EC1 and EC2 domains. In turn,
these antibodies would bind to the EC1 and EC2 domain
of Dsg1 and induce skin blistering. The IgG subclass of the
anti-Dsg1 autoantibodies generated in the two phases is
likely to be influenced by cytokines released during each
stage of the immune response in these patients. The initial
phase might be driven by Th0 or both Th1 and Th2 cyto-
kines and therefore the anti-Dsg1 autoantibodies generated
in this phase are IgG1 and IgG4 subclass (16, unpublished
data). In the second phase, primed T cells are mainly Th2
type (30) and consequently, pathogenic autoantibodies are
predominantly of IgG4 subclass (1). However, it appears
that the EC1 or EC2 epitopes are the drivers of the patho-
genicity of the anti-Dsg1 autoantibodies rather than the IgG
subclass. Indeed, we have studied a PF patient with IgG1
anti-Dsg1 autoantibodies specific for the EC1 and EC2 do-
mains, which are pathogenic when tested on the passive
transfer mouse model (31).
The two-phase model is supported by a recent study in
our laboratory (unpublished data) that shows that a signifi-
cant number of patients with diseases in which hematopha-
gous vectors are involved in the transmission of the illness,
i.e., onchocerciasis (black flies), leishmaniasis (sand flies),
and Chagas disease (kissing bugs) possess antibodies against
the EC5 domain of Dsg1. Onchocerciasis and Chagas dis-
ease are unknown in the Limao Verde reservation, where
FS is prevalent, but it is well documented that inhabitants
of this settlement are constantly bitten by black flies, kissing
bugs, and sand flies (unpublished data). The authors hy-
pothesize that a salivary antigen(s) from these blood-feed-
ing insects may contain a cross-reactive molecule(s) that
triggers the anti-Dsg1 EC5 antibody response.
The incubation time between the first and the second
phase of FS could last as long as 7 yr as observed in one pa-
tient. Numerous factors may influence epitope spreading,
including the HLA alleles (25, 32, 33). It is known that FS
is strongly associated with certain HLA-DRB1 alleles, such
as DRB1*0404, *1402, *1406, or *0102 (34, 35) alleles,
which encode a shared peptide sequence at positions 67–74
in the P4 pocket of hypervariable DR 1 chain. These FS-
susceptibily alleles are not frequently found in normal indi-
viduals possessing anti-Dsg1 antibodies specific for the EC5
domain (unpublished data). It is possible that antigen-pre-
Figure 7. A model of the immunopathogenic pathway of FS. Environ-
mental factor(s) trigger the production of nonpathogenic IgG1 and IgG4
antibodies against the EC5 domain of Dsg1. In certain genetically pre-
disposed individuals, intramolecular epitope spreading results in the
generation of predominantly IgG4 antibodies, against the EC1 and EC2
domains of Dsg1, that induce disease.T
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senting cells expressing these susceptibility HLA-II alleles
are capable of presenting Dsg1 peptides to T cells bearing
specific receptors for EC1 or EC2 epitopes. These T cells
in turn would stimulate EC1- and EC2-specific B cells to
produce anti-EC1 and anti-EC2 autoantibodies.
One interesting finding in this study is the dynamic
change in epitope specificities during the time course of the
disease. Anti-EC1 and anti-EC2 autoantibodies disappeared
with disease remission and reappeared with disease relapses.
EC5-specific antibodies were present mainly in patients
during disease onset or clinical relapse, and persisted during
remission. These findings clearly demonstrate that the anti-
Dsg1 immune response in FS is dynamic and that anti-
EC1/EC2 autoantibodies correlate well with the clinical
activity of the disease. The immunological mechanism re-
sponsible for the elimination of anti-EC1/EC2 antibodies
in FS patients during drug-induced remission or spontane-
ous remission, reported to be around 10% (36), remains un-
known. Although the mechanism regulating the recurrence
of the anti-EC1 and anti-EC2 antibodies during disease re-
lapses is not clear, it is possible that the reappearance these
antibodies during disease relapse may result from reactiva-
tion of memory B and T cells by reexposure to self-Dsg1.
Although the majority of patients with active disease
possess a mixture of anti-EC1 and anti-EC2 antibody pop-
ulations, a few sera possessed antibodies to EC1 without
EC2, or to EC2 without EC1. This observation indicates
that autoantibodies against EC1 and EC2 recognized at
least two distinct epitopes, and either one alone maybe ca-
pable of causing disease (31). This finding suggests that
both the EC1 and EC2 domains of Dsg1 are relevant in the
mechanism of acantholysis (cell–cell detachment) induced
by anti-Dsg1 autoantibodies.
Another interesting finding of this study was the identifi-
cation of several sera from FS patients and normal subjects
living in the Limao Verde reservation that contained anti-
bodies against the ectodomain of Dsg3. Patients and normal
individuals exhibiting anti-Dsg3 antibodies in their sera did
not have mucosal lesions, typical of pemphigus vulgaris, a
disease characterized by anti-Dgs3 autoantibodies. It should
be noted that the anti-Dsg3 reactivity of the majority of sera
was weak. However, in 12% of the sera from FS patients
with active disease (n   25) we observed a fairly good IP re-
activity with the ectodomain of Dsg3. These findings are in
agreement with a recent study reported by Arteaga et al. (37)
that found anti-Dsg3 antibodies in 18 out of 241 FS sera
tested by an ELISA assay using the recombinant ectodomain
of Dsg3 (7.5%). It is feasible that anti-Dsg3 and anti-Dsg1
autoantibodies in these sera represent distinct populations of
antibodies or perhaps Dsg1/Dsg3 cross-reactive antibodies.
This finding may also leave open the possibility that in some
rare individuals the anti-Dsg3 response may lead to an en-
demic form of pemphigus vulgaris as suggested by a prelimi-
nary report from Brazilian investigators (38).
In conclusion, our data provide new insights into the
immunopathogenesis of FS. These findings may be ex-
tended to the nonendemic form of PF and to other forms
of pemphigus, and may also have implications to other an-
tibody-mediated autoimmune diseases. Rather than using
the entire Dsg1 ectodomain, the specific detection of anti-
EC1/EC2 and anti-EC5 autoantibodies might be more re-
liable for the diagnosis of FS and for the monitoring of dis-
ease remission and relapse. This study may facilitate the
identification of a subset of normal individuals living in
Limao Verde who are at risk to develop FS, namely those
carrying susceptible HLA class II alleles and possessing anti-
Dsg1 EC5 autoantibodies. Finally, the results of these stud-
ies may enhance the chances of identifying the environ-
mental trigger for FS.
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